Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376711 | 0.93 | ALDH1A1 (0.37) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL15604295 | 0.91 | ALDH1A1 (0.36) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL3178526 | 0.90 | ALDH1A1 (0.38) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL3020149 | 0.89 | CA14 (0.49) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL15549015 | 0.88 | ALDH1A1 (0.34) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL15549014 | 0.88 | ALDH1A1 (0.34) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL23540791 | 0.87 | ALDH1A1 (0.36) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL3024404 | 0.87 | CA14 (0.48) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL15668049 | 0.87 | SSTR4 (0.41) | ALDH1A1CA14DPP4HDAC6HDAC1 | |
| SCHEMBL15942130 | 0.87 | CA14 (0.38) | ALDH1A1CA14DPP4HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4049841-B1 | HYBRID RESIN COMPOSITION | CUBICURE GMBH (AT) | 2026-03-18 | — | — | EP | claimed |
| US-12390987-B2 | Hybrid resin composition for the 3D-printing of objects | CUBICURE GMBH (AT) | 2025-08-19 | — | — | US | claimed |
| US-20240198582-A1 | HYBRID RESIN COMPOSITION FOR THE 3D-PRINTING OF OBJECTS | CUBICURE GMBH (AT) | 2024-06-20 | — | — | US | claimed |
| WO-2022180566-A1 | HYBRID RESIN COMPOSITION FOR THE 3D-PRINTING OF OBJECTS | CUBICURE GMBH (AT) | 2022-09-01 | — | — | WO | claimed |
| EP-4049841-A1 | HYBRID RESIN COMPOSITION | Cubicure GmbH (AT) | 2022-08-31 | — | — | EP | claimed |
| EP-4049841-B1 | HYBRID RESIN COMPOSITION | CUBICURE GMBH (AT) | 2026-03-18 | — | — | EP | disclosed |
| US-12390987-B2 | Hybrid resin composition for the 3D-printing of objects | CUBICURE GMBH (AT) | 2025-08-19 | — | — | US | disclosed |
| US-20240198582-A1 | HYBRID RESIN COMPOSITION FOR THE 3D-PRINTING OF OBJECTS | CUBICURE GMBH (AT) | 2024-06-20 | — | — | US | disclosed |
| WO-2024105509-A1 | RESIN COMPOSITION | CUBICURE GMBH (AT) | 2024-05-23 | — | — | WO | disclosed |
| EP-4369098-A1 | RESIN COMPOSITION | Cubicure GmbH (AT) | 2024-05-15 | — | — | EP | disclosed |
| US-20230149911-A1 | RUTHENIUM-BASED METATHESIS CATALYSTS, PRECURSORS FOR THEIR PREPARATION AND THEIR USE | UMICORE AG & CO. KG (DE) | 2023-05-18 | — | — | US | disclosed |
| US-20230149911-A1 | RUTHENIUM-BASED METATHESIS CATALYSTS, PRECURSORS FOR THEIR PREPARATION AND THEIR USE | UMICORE AG & CO. KG (DE) | 2023-05-18 | — | — | US | disclosed |
| WO-2012058116-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-8124773-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124773-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2354138-A1 | Compounds and compositions for treatment of cancer | Sunesis Pharmaceuticals, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2011008110-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2007146335-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149911-A1 | RUTHENIUM-BASED METATHESIS CATALYSTS, PRECURSORS FOR THEIR PREPARATION AND THEIR USE | HMBS, RRP12, RNF168 | ALDH1A1 844/4885CA14 2897/4885DPP4 3394/4885 |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | ALDH1A1 2487/4885CA14 2382/4885DPP4 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.